Building on the fact that follistatin gene transfer Phase l/ll in humans have been effective in patients with BMD with residual dystrophin function, follistatin gene upregulation using CRISPRa could, with much development, be used for DMD treatment and complement the current dystrophin restorative therapies. Here, FST is linked to Duchenne muscular dystrophy.